Abstract: The present invention describes compositions and methods for treating and preventing non-degenerative neurological diseases and disorders associated with elevated sPLA2 activity as well as cardiovascular diseases using a CHEC peptide to inhibit sPLA2 activity.

Abstract: Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue.

Abstract: This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Abstract: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFR? antagonist. The invention also provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFR?, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Abstract: The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression of viral activity by CVN with the allosteric suppression of viral envelope binding to both CD4 and co-receptor by 12p1.

Abstract: A method and apparatus for fabricating microbraided structures is provided. A microbraiding device includes first and second carrier members that are movable with respect to each other. Each carrier includes a plurality of shelters. Spool-less strands of microfiber are retained in shuttles that are movable between the first and second shelters under magnetic forces. The microbraid structure is fabricated as the shuttles move between the first shelters, and as the first carrier member moves relative to the second carrier member.

Abstract: Provided herein is a suitable method for detecting the presence or absence of a cancer in an individual, by determining the level of methylation of the sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of detecting the presence or absence a cancer in an individual by determining if there is an apparent 100% methylation by assay of the CpG sites in the anti-sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of tissue typing by determining the level of methylation of the anti-sense strand of a selected regulatory region of a tumor suppressor gene indicating an enhanced likelihood that a tissue is liver.

Abstract: Inventors have developed a chromophore (nitrodibenzylfuranyl, or NBDF) for ultra efficient uncaging of a caged substrate (e.g., an organic molecule such as, for example, an amino acid, a biological molecules, such as, for example, second messengers inside cells). Photolysis of a NBDF derivative of EGTA (i.e. caged calcium) is about 50 times more efficient than others calcium cages (the quantum yield of photolysis is 0.6 and the extinction coefficient is 18,400. NDBF-EGTA has a 2-photon cross section of about 0.3-0.6 GM).

Abstract: Provided are methods of diagnosing and/or determining treatment of non-urinary tract cancers by detecting biomarkers, and aberrant methylation in said biomarkers, in human urine samples

Abstract: Methods for treating a neoplastic disease in a mammalian subject are provided. The method provides administering an inhibitor of O-GlcNAc transferase in an amount effective to reduce or eliminate the neoplastic disease in the mammalian subject. Method for diagnosing a risk factor for a neoplastic disease in a mammalian subject and methods for identifying a test compound which inhibits a hexosamine signaling pathway in a cell or tissue are provided.

Abstract: Methods for preventing or treating an Apicomplexan parasite infection in a patient administering to a patient in need thereof an effective amount of a compound of Formulas I-IV.

Abstract: Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.

Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use.

Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.

Abstract: The present invention provides compositions and methods useful in the prevention and treatment of HIV-1 infection in a host subject. High affinity binding of an allosteric dual antagonist to HIV-1 gp120 induces a conformational change in the gp 120 protein that traps the gp 120 protein in a three-dimensional structure that suppresses its function and exposes novel antigenic epitopes to host immune surveillance.

Abstract: The present invention relates to photolabile or photoreleasable compounds including a caging moiety linked to an effector moiety, wherein the compounds are capable of releasing the effector moiety on irradiation, typically by flash irradiation with light. These compounds are particularly suitable for focal 2-photon uncaging The photoreleasable compounds can be used to deliver effector moieties such as carboxylic acids, preferably, neuroactive amino acids to sites where their activity is required. In preferred embodiments of the invention, the caging moiety is based on 4-carboxymethoxy-5,7-dinitroinlinyl and derivatives thereof.

Abstract: A device for providing extracorporeal cardiac pacing. The device includes an ultrasound transducer mountable to the external thorax of a patient and an ultrasound generator for transmitting ultrasound pulses to the ultrasound transducer. The heart rate of a patient is monitored by the device. A controller evaluates the heartbeat as compared with threshold criteria for stimulation of the heart and causes the ultrasound generator to deliver ultrasound pulses to the ultrasound transducer at a prescribed intensity, frequency, and pulse duration.

Abstract: The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression of viral activity by CVN with the allosteric suppression of viral envelope binding to both CD4 and co-receptor by 12p1.

Abstract: Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.

Abstract: The present invention relates to methods useful to monitor central and peripheral nervous system neuron/axon destruction resulting from an increase in acute phase inflammatory enzymes. The methods have applicability to monitoring the progress of neurological diseases, including multiple sclerosis and Alzheimer's disease, as well as neuroinflammatory damage that results from sports injuries, vigorous physical activity or any form of physical abuse. The invention further relates to methods of treating multiple sclerosis or other diseases with an inflammatory component related to phospholipase A2.